Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06418711 Not yet recruiting - Clinical trials for Mycobacterium Infections, Nontuberculous

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

ICoN-1
Start date: June 2024
Phase: Phase 3
Study type: Interventional

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to Guideline-based therapy (GBT).

NCT ID: NCT06416163 Not yet recruiting - Clinical trials for Pulmonary Hypertension

FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion

FIBRINOX-EXTRA
Start date: July 1, 2024
Phase:
Study type: Observational

This is an observational clinical research study investigating patients with fibrotic interstitial lung disease (fILD), also known as pulmonary fibrosis. It is not known why some patients with fILD clinically deteriorate. This study will investigate whether measuring oxygen levels during sleep or exercise can help identify patients who are at increased risk of clinical deterioration.

NCT ID: NCT06409299 Not yet recruiting - Bronchiectasis Clinical Trials

Enhancing Lung Health in Kids With Structural Lung Damage and Malformations: Azithromycin (AZI) for Airway Infection Prevention

TRALULALA-AZI
Start date: September 1, 2024
Phase: Phase 3
Study type: Interventional

Children with lung and airway malformations or early structural lung damage face significant challenges, often leading to recurrent respiratory infections, hospitalizations, and decreased quality of life. Despite various interventions, effective strategies are urgently needed. The link between these conditions and persistent bacterial bronchitis remains unclear, possibly due to compromised airways and reduced mucociliary clearance. Although antibiotics can alleviate symptoms, relapse is common. Experts often prescribe prophylactic azithromycin, despite limited evidence of its benefits. Azithromycin shows promise due to its anti-inflammatory and immunomodulatory effects but lacks thorough evaluation in this population. To address this gap, we propose a double-blind, randomized controlled trial to assess azithromycin's effectiveness and safety in preventing respiratory infections in children with these conditions. This research aims to inform clinical practice and improve the health of affected children and their families.

NCT ID: NCT06399094 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Patients With Cystic Fibrosis, Pulmonary Fibrosis or COPD (Chronic Obstructive Pulmonary Disease)

ATF/SPP
Start date: June 1, 2024
Phase:
Study type: Observational

The main objective of the study is to assess the potential of time-frequency representation and analysis of pulmonary sounds collected with an electronic stethoscope, as part of the routine monitoring of patients with cystic fibrosis, COPD or pulmonary fibrosis.

NCT ID: NCT06388421 Not yet recruiting - Clinical trials for Pulmonary Hypertension

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Start date: August 1, 2024
Phase:
Study type: Observational

This is a prospective, non-interventional, multicenter, registry of patients with pulmonary associated with interstitial lung disease (PH-ILD).

NCT ID: NCT06385301 Not yet recruiting - Clinical trials for Lung Diseases, Obstructive

Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases

Start date: May 2024
Phase: N/A
Study type: Interventional

The investigators aim to study the effect of SOT in subjects with chronic lung disease in submaximal exercise.

NCT ID: NCT06376084 Not yet recruiting - Neoplasms Clinical Trials

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

FOREFRONT
Start date: July 24, 2024
Phase:
Study type: Observational

To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS.

NCT ID: NCT06346691 Not yet recruiting - COPD Clinical Trials

Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease

Start date: April 16, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to determine if doxofylline and procaterol are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs. The main questions it aims to answer are: - Does doxofylline demonstrate a comparable bronchodilator effect to procaterol in COPD participants? - What medical problems do participants experience when taking doxofylline and procaterol?"

NCT ID: NCT06346678 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Accuracy of Accuhaler Tester, Ellipta Tester and Turbutester in Patients With Chronic Obstructive Pulmonary Disease

Start date: April 16, 2024
Phase:
Study type: Observational

The goal of this observational study is to investigate the accuracy of Accuhaler tester, Ellipta tester and Turbutester in patients with chronic obstructive pulmonary disease (COPD). The main question it aims to answer is: • Do Accuhaler tester, Ellipta tester, and Turbutester demonstrate comparable accuracy to the In-check DIAL for assessing inspiratory inhalation force in COPD patients?

NCT ID: NCT06336798 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Bioenergetic Effect of Pioglitazone in CLD-PH

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD. Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo).